Haematology
Service
Fundación Hospital Alcorcón
Alcorcón, EspañaPublications in collaboration with researchers from Fundación Hospital Alcorcón (19)
2023
-
Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain
European Journal of Haematology, Vol. 111, Núm. 3, pp. 485-490
-
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
Cancers, Vol. 15, Núm. 4
2022
-
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270
2021
2020
-
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country
Experimental Hematology and Oncology
-
Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort
Thrombosis and Haemostasis, Vol. 120, Núm. 3, pp. 437-448
2018
2016
-
Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial
Annals of Hematology, Vol. 95, Núm. 6, pp. 893-899
-
Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients
Acta Haematologica, Vol. 136, Núm. 2, pp. 76-84
-
Molecular and clinical profile of von willebrand disease in spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm
Thrombosis and Haemostasis, Vol. 115, Núm. 1, pp. 40-50
-
Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma
European Journal of Haematology, Vol. 96, Núm. 5, pp. 532-540
2014
-
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial
The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111
-
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?
Blood, Vol. 124, Núm. 12, pp. 1887-1893
2012
-
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
Blood, Vol. 120, Núm. 13, pp. 2581-2588
2011
-
Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab
Expert Review of Hematology, Vol. 4, Núm. 1, pp. 9-16
2010
-
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial
The Lancet Oncology, Vol. 11, Núm. 10, pp. 934-941
-
Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era
European Journal of Haematology, Vol. 85, Núm. 4, pp. 321-328
2008
-
Body mass index and mortality in patients with acute venous thromboembolism: Findings from the RIETE registry
Journal of Thrombosis and Haemostasis, Vol. 6, Núm. 4, pp. 595-600